Ayi watsi da saƙonnin masu adawa da allurar rigakafi da wasu ƙarairayin- Alluran rigakfin Covid-19 basu ne na farko ba wajen bada alluran rigakafi fiye da sau ɗaya

Wani  rubuta a Facebook da akayi da yaren Afrikaans, aka kuma yaɗa da kwafar sa sau da dama a Afrika ta Kudu, na nufin cewa alluran rigakafin Covid-19, waɗanda wasu daga ciki ake yin su fiye da sau ɗaya ba alluran rigakafi na “asali” ba ne.

Rubutun na cewa: “Met alle vorige ware (egte) vaksiene (masels, pokke, TB, polio, pampoentjies, waterpokkies, meningitis) was ek slegs eenmaal ingeent en klaar. Geen tweede of derde spuite nie).”

Wannan na nufin: “Duk alluran rigakafi (ƙyanda, ƴanrani, tarin fuka, shan inna, hangun, farankama, sanƙarau) na asali (gaske) sau ɗaya kawai aka yi mun allura. Babu wata allura a karo na biyu ko na uku.”

Amma hakan ba gaskiya ba ne, sannan rubutun ya yi wasu iƙirari na ƙarya akan alluran rigakafin Covid-19.

Alluran rigakafi da dama na buƙatar ayi su sau da dama, har na cututtukan da aka ambata

Duk da cewa rubutun na Facebook ya ambato wasu jerin alluran rigakafi, waɗanda rubutun ya ce ba’a buƙatar ayi su sau biyu ko uku, da dama daga waɗannan allurai ana yin su fiye da sau ɗaya. 

Hukumar lafiya ta duniya (WHO) na bada shawarar ayi allurar rigakafin ƙyanda har sau biyu ga yara ƙanana “don tabbatar  da samuwar garkuwar jiki da kuma kiyaye barkewar cutar, domin kashi 15% na waɗanda aka yiwa allurar sau ɗaya jikin su baya samar da garkuwa daga cutar”.

Kibiyar kiyaye cututtaka masu yaɗuwa ta Amurka (CDC) na bada shawarar a tsara a yi allurar rigakafin shan inna har sau huɗu ga yara ƙanana. Sun kuma ƙara bada shawarar cewa “manyan da ke cikin barazanar kamuwa da shan inna” a ayi musu allurar rigakafin sau ɗaya a rayuwa, ko da anyi musu tun suna ƙanana.

CDC ta kuma ƙara bada shawarar ayi allurar rigakafin farankama har sau biyu ga duk nau’in mutane, bayan an tsara ta kashi-kashi tare da la’akari da shekaru, ko da mutum ya ci karo da ƙwayar cutar. 

Daga cikin alluran rigakafin Covid-19 da ake da su, duk da dai ba duka ba, suna buƙatar ayi su sau biyu, hakan kuma ba wani abu ne daban ko na ban mamaki ba.

An amince da amfani da alluran rigakafin Covid-19, ba ‘gwaji’ ake ba

Wannan rubutu na Facebook mai karkatar da tunani, yayi iƙirarin cewa allurar rigakafin Covid-19 “is nog st eksperimentele fase” da kuma “sal eers twee jaar (of langer) van nou af klaar wees met kliniese proewe en die laboratorium fase”. Wanda ke nufin, allurar rigakafin “na cikin gwaji kuma “gwajin da fitar su daga ɗakin gwaji zai ɗauki tsahon shekaru biyu (ko fiye da haka) kafin a gama a halin yanzu”.

Ba wannan ne karo na farko ba da aka yi iƙirarin alluran rigakafin Covid-19 na “gwaji ne” ko kuma ba’a gwada ingancin su ba. Sai dai kafin a amince da ayi amfani da alluran rigakafi ko kuma kowanne irin magani dole ne su bi matakan tantancewa da amincewa a duk ƙasashe, kuma haka yake akan allurar rigakafin Covid-19 ma. 

Africa Check ta wallafa wasu bayanai a tattare akan yadda ake amincewa da allurar rigakafi a Afrika ta Kudu, Najeriya da Kenya.

Duka alluran rigakafin da aka amince a yi amfani da su don kiyaye ɗaukar Covid-19 an same su marasa hatsari ne kuma masu inganci bayan an yi musu babban gwajin kiwon lafiya. 

Alluran rigakafi na rage hatsarin kamuwa ko mutuwa daga cutar Covid

Rubutun yayi iƙirarin cewa “doen eintlik alle ander skadelike dinge, BEHALWE die EEN ding wat dit veronderstel is om te doen: om mense teen die virus te immuniseer”. Wannan na nufin allurar rigakafin “na yin abubuwan cutarwa da dama, BANDA abu ƊAYA da ya kamata tayi: kiyaye mutane daga kamuwa da ƙwayar cutar”.

Wannan ma ba gaskiya ba ne. Ba kawai gwajin kiwon lafiya ne ya tabbatar da ingancin alluran rigakafin ba, amma kasancewar ƙasashe na ta yiwa jama’ar su da yawa allurar rigakafin, ana ta samun yawaitar hujjoji bayyanannu cewa allurar rigakafin na rage hatsarin kamuwa ko mutuwa daga Covid-19. 

A nazari guda biyu da akayi a Israel, inda aka yiwa jama’a da yawa allurar rigakafi cikin lokacin kankani, an samu cewa allurar rigakafin Covid-19 ta Pfizer BioNTech ta rage yiwuwar kamuwa ko mutuwa daga Covid-19.

A nazari na farko, wanda aka buga a mujallar magunguna ta New England a watan Afrilu 2021, an yi nazari akan jama’a sama da 600,000 da aka kasa kashi biyu, kashi na farko suka karɓi allurar rigakafin, kashi na biyu basu karɓa ba. An tabbatar da ingancin allurar rigakafin wajen kiyayewa, kamuwa da mutuwa daga cutar Covid-19, da kuma wasu sakamakon, waɗanda suka tabbatar da sakamakon gwajin kiwon lafiya akan allurar rigakafin.

Nazari na biyu, wanda aka wallafa a Lancet a watan Mayu, ya tabbatar cewa allurar rigakafin “na da matuƙar inganci akan mutane a kowacce al’umma waɗanda ke da shekaru daban-daban […] wajen kiyaye kamuwa da ƙwayar cutar SARS-CoV-2 mai nuna alamu da mara nuna alamu da kuma mai kwantarwa, da mai sa matsananciyar rashin lafiya ko kisa daga Covid-19”.

A bitar wasu manyan nazare-nazare da akayi a duniya, daga watan Agusta, an yi nazarin ingancin alluran rigakafin Covid-19 guda uku a ƙasashe biyar. Daga cikin wasu bincike da aka yi, rahoton ya bayyana cewa: “Abu mafi muhimmanci shine, alluran rigakafin da ake da su, su ne mafiya inganci wajen kiyaye manya a matakin shekaru daban-daban daga matsananciyar rashin lafiya ko mutuwa daga Covid-19.”

Babu wata hujjar da ta tabbatar da waɗannan da’awowi masu karkatar da tunani da aka yi a rubutun na Facebook. Amma akwai hujjoji da dama da suka tabbatar alluran rigakafin da ake dasu akan Covid-19, waɗanda akeyi sau ɗaya ko sau biyu, suna hana yaɗuwa da mutuwa daga ƙwayar cutar.